Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025. This achievement comes on the heels of Armis being named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest scores possible in 9 key criteria. According to the report, “Armis’ vision centers on delivering enterprise-wide ...

Rapid Medical™, a leading developer of active endovascular devices, announces that its DRIVEWIRE™ 24 steerable guidewire has been used in more than 1,000 neurovascular procedures in North America during a limited commercial launch beginning earlier this year. The company also announced receipt of CE Mark under the European Medical Device Regulation (MDR), as presented at the 2025 ESMINT Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire...

AppLogic Networks, a leader in software-based application visibility and performance optimization, today announced that a leading, next-generation managed service provider has adopted its AI-powered visibility platform, focused on end customers’ high value, high expectation digital experiences, including for maritime travel. The deployment reflects a pivotal industry shift: Quality of Experience (QoE) is no longer a technical metric; it’s a business imperative. Vacationers on cruise ships spe...

Lofted Custom Spirits, the nation’s first and leading custom contract whiskey distiller, today announced the launch of a new Alternating Proprietorship program, allowing partners to take advantage of significantly reduced excise tax rates. Using their own DSP license and Lofted’s dedicated processing facility, craft brands can get the full benefit of Craft Beverage Modernization Act (CBMA) tax breaks and save an average $6 per proof gallon. This press release features multimedia. View the full...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment...